<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17401" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alpha-Blockers</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nachawati</surname>
            <given-names>Dana</given-names>
          </name>
          <aff>Michigan State University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Jayesh B.</given-names>
          </name>
          <aff>University of Iowa Hospitals and Clinics</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dana Nachawati declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayesh Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17401.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Alpha-blockers are medications used in the management and treatment of essential hypertension, benign prostatic hyperplasia (BPH), and pheochromocytoma. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of alpha-blocker therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with conditions as mentioned above.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of alpha-blockers.</p></list-item><list-item><p>Describe the adverse effects and contraindications of alpha-blockers.</p></list-item><list-item><p>Outline the appropriate monitoring and management for the toxicity of alpha-blockers.</p></list-item><list-item><p>Review some interprofessional team strategies for improving care coordination and communication to improve outcomes in alpha-blocker therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17401&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17401">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17401.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Alpha-blockers fall into three different categories.</p>
        <p>
<bold>1. Nonselective Alpha-blockers (alpha-1&#x000a0; and&#x000a0;alpha-2)</bold>
</p>
        <p>Nonselective alpha-blockers include phenoxybenzamine and phentolamine. Both of these medications have FDA approval for use in patients with pheochromocytoma.&#x000a0;</p>
        <p>Phenoxybenzamine is irreversible and phentolamine is reversible alpha-blockers.&#x000a0;Both are used intraoperatively to manage hypertensive crisis during pheochromocytoma removal.<xref ref-type="bibr" rid="article-17401.r1">[1]</xref><xref ref-type="bibr" rid="article-17401.r2">[2]</xref></p>
        <p>Phentolamine sees occasional use in the treatment of cocaine-induced cardiovascular complications. In this situation, the use of &#x003b2;-blockers is less desirable due to the risk of unopposed &#x003b1;-adrenergic receptor-mediated coronary vasoconstriction and hypertension. Although it is worth mentioning that it is not a first-line agent for this&#x000a0;condition.&#x000a0;</p>
        <p>
<bold>2. Selective Alpha-1 Blockers</bold>
</p>
        <p>Selective alpha-1 blocker ends with the suffix "-osin."&#x000a0;These medications include alfuzosin, doxazosin, terazosin, tamsulosin, and prazosin.</p>
        <p>These medications are FDA approved to treat benign prostatic hyperplasia (BPH).&#x000a0;</p>
        <p>These medications may also be options to treat essential hypertension. However, they are not typically first-line&#x000a0;agents for the management of hypertension.<xref ref-type="bibr" rid="article-17401.r3">[3]</xref></p>
        <p>
<bold>3. Selective Alpha-2 Blockers</bold>
</p>
        <p>Selective alpha-2 blockers include the medications yohimbine and idazoxan.</p>
        <p>Yohimbine&#x000a0;has been used to treat male sexual dysfunction, although the&#x000a0;effectiveness has not yet been established and is not currently FDA approved for this use or any other uses.</p>
        <p>Idazoxan is being used&#x000a0;in research, but has no established clinical role has established.<xref ref-type="bibr" rid="article-17401.r4">[4]</xref></p>
      </sec>
      <sec id="article-17401.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Alpha-blockers produce their pharmacological effects through alteration of the sympathetic nervous system.</p>
        <p>There are two types of alpha-adrenergic receptors: alpha-1 and alpha-2. Most of the alpha-1 adrenergic receptors are located on the vascular smooth muscle (in the skin, sphincters of the gastrointestinal system, kidney, and brain) and cause vasoconstriction when activated by catecholamines such as epinephrine and norepinephrine (NE).&#x000a0;The&#x000a0;vasoconstriction&#x000a0;causes an increase in both systemic arterial blood pressure and peripheral resistance. Norepinephrine has a higher affinity for this receptor than epinephrine. Alpha-2 adrenergic receptors are located on peripheral nerve endings and inhibit the release of NE when activated; this provides a feedback mechanism for NE to inhibit its release.<xref ref-type="bibr" rid="article-17401.r5">[5]</xref></p>
        <p>Nonselective alpha-adrenergic antagonists cause vasodilation by blocking both alpha-1 and alpha-2 receptors. The blockage of alpha-2 receptors will increase the NE&#x000a0;release, which will reduce the force of the vasodilation induced by the blockade of the alpha-1 receptors. These medications work best when there is increased sympathetic activity such as during stress or when there is an increase in circulating catecholamines, making these medications useful for patients with pheochromocytoma.<xref ref-type="bibr" rid="article-17401.r5">[5]</xref></p>
        <p>Selective alpha-1 adrenergic antagonists cause vasodilation by preventing NE from activating the alpha-1 receptor, resulting in a lowering of the blood pressure, allowing alpha-1 blockers to be used for hypertension. Alpha-1 blockers also cause relaxation of smooth muscle in the prostate, which can enable the urine to flow more freely thru the urethra, making the medications useful for the management of benign prostatic hyperplasia (BPH).<xref ref-type="bibr" rid="article-17401.r3">[3]</xref><xref ref-type="bibr" rid="article-17401.r5">[5]</xref>&#x000a0;</p>
        <p>Selective alpha-2 adrenergic antagonists inhibit negative feedback of NE, stimulating the sympathetic nervous system. However, there are limited findings on the significance of this mechanism of action in human medicine.<xref ref-type="bibr" rid="article-17401.r5">[5]</xref></p>
      </sec>
      <sec id="article-17401.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Phenoxybenzamine is an oral medication that can be started 10 to 14 days before the excision of the pheochromocytoma. Phentolamine is used as an adjunct during the removal of pheochromocytoma and can be administered either intramuscularly or&#x000a0;intravenously.<xref ref-type="bibr" rid="article-17401.r6">[6]</xref></p>
        <p>Selective alpha-1 blockers are oral medications best taken at night to minimize orthostatic hypotension.</p>
        <p>Yohimbine, a selective alpha-2 blocker, is administered orally and is discontinued as a prescription drug in the USA.<xref ref-type="bibr" rid="article-17401.r7">[7]</xref><xref ref-type="bibr" rid="article-17401.r4">[4]</xref></p>
      </sec>
      <sec id="article-17401.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of nonselective alpha-blockers include hypotension, weakness, tachycardia, and tremulousness. Hypotension is due to inhibition of the alpha-1 receptors, which causes vascular smooth muscle relaxation and vasodilation. The remaining adverse effects occur due to the increased release of norepinephrine when alpha-2 receptors become&#x000a0;simultaneously&#x000a0;antagonized. This release results in the stimulation of beta receptors due to the spillover of norepinephrine and results in tremulousness and tachycardia.<xref ref-type="bibr" rid="article-17401.r8">[8]</xref></p>
        <p>Adverse systemic effects such as tachycardia and tremulousness are less common with selective alpha-1 blockers. Although it can cause first-dose hypotension, syncope, dizziness, and headache due to vasodilation and vascular smooth muscle relaxation. Reflex tachycardia may occur due to a sudden decrease in blood pressure. These adverse effects tend to occur more often in the elderly and increase the risk of falls. To best avoid these adverse effects, the patient should take the medication at night.<xref ref-type="bibr" rid="article-17401.r8">[8]</xref></p>
      </sec>
      <sec id="article-17401.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Alpha-blockers are contraindicated in individuals with hypersensitivity to alpha-blockers or any other component of the drug formulation.</p>
        <p>Caution is necessary when administering alpha-blockers in elderly patients or if previous cataract surgery. These medications can complicate cataract surgery by inducing sudden iris prolapse and pupil constriction during the surgery - also known as "intraoperative floppy iris syndrome."<xref ref-type="bibr" rid="article-17401.r3">[3]</xref><xref ref-type="bibr" rid="article-17401.r9">[9]</xref></p>
        <p>Nonselective alpha antagonists have additional contraindications. Phenoxybenzamine and phentolamine are contraindicated in a breastfeeding mother. Clinicians should exercise caution if the patient has marked renal impairment, cerebrovascular disease, coronary artery disease, or current respiratory infection. These medications are not suitable for long-term use.<xref ref-type="bibr" rid="article-17401.r8">[8]</xref></p>
      </sec>
      <sec id="article-17401.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Due to the risk of hypotension and tachycardia with phentolamine, it is crucial to monitor blood pressure and heart rate when administered intraoperatively for the removal of pheochromocytoma.<xref ref-type="bibr" rid="article-17401.r10">[10]</xref></p>
        <p>No routine monitoring or tests are currently recommended for the rest of the alpha antagonists.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-17401.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Alpha-blockers are frequently prescribed in the elderly male population, and toxicity is common in these individuals. The&#x000a0;most common&#x000a0;adverse effect is hypotension.&#x000a0;Extremely low blood pressure&#x000a0;can&#x000a0;cause ischemic insult to major organs and increase the fall risk. If toxicity suspected, general measures are necessary to&#x000a0;optimize the blood pressure.<xref ref-type="bibr" rid="article-17401.r11">[11]</xref>&#x000a0;If a patient is hypotensive,&#x000a0;he should be moved to a supine position until blood pressure and heart rate are acceptable. If the patient remains hypotensive, then the patient can be managed with fluid resuscitation. If necessary, vasopressors could be administered as a last resort.<xref ref-type="bibr" rid="article-17401.r12">[12]</xref> There is no specific antidote available.&#x000a0;</p>
      </sec>
      <sec id="article-17401.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Preventing adverse effects of medications in the elderly population requires special care and communication between physicians, pharmacists, and nurses. Selective alpha-1 antagonists are commonly used agents in an outpatient setting for patients with benign prostatic hypertrophy. These drugs can have significant interactions with other medications that have similar adverse effects. Clinical staff must review in detail the medical and social history of the patient before prescribing and ordering an alpha-blocker.</p>
        <p>If a patient taking an alpha-blocker resides in a nursing facility, there should be close communication with the nursing staff closely monitoring the patient due to an increased risk of orthostatic hypotension, which can lead to a fall. Fall precautions such as bed rails, a bed alarm, and a floor protection fall mat should be a consideration. The administration of alpha-blockers requires an interprofessional team that includes physicians, pharmacists, and nurses to collaborate to prevent adverse effects, especially in the elderly.</p>
      </sec>
      <sec id="article-17401.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17401&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17401">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17401/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17401">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17401.s11">
        <title>References</title>
        <ref id="article-17401.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Clinical effects of prophylactic use of phentolamine in patients undergoing pheochromocytoma surgery.</article-title>
            <source>J Clin Anesth</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>44</volume>
            <fpage>119</fpage>
            <pub-id pub-id-type="pmid">29195099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sambhunath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pankaj</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Usha</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Role of phenoxybenzamine in perioperative clinical practice.</article-title>
            <source>Ann Card Anaesth</source>
            <year>2015</year>
            <season>Oct-Dec</season>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-8</page-range>
            <pub-id pub-id-type="pmid">26440247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <chapter-title>Alpha 1 Adrenergic Receptor Antagonists</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>1</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">31644028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kovell</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Terlecki</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>A Urologist's Guide to Ingredients Found in Top-Selling Nutraceuticals for Men's Sexual Health.</article-title>
            <source>J Sex Med</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>2105</fpage>
            <page-range>2105-17</page-range>
            <pub-id pub-id-type="pmid">26531010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nash</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism.</article-title>
            <source>Clin Cardiol</source>
            <year>1990</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>764</fpage>
            <page-range>764-72</page-range>
            <pub-id pub-id-type="pmid">1980236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naranjo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>YN</given-names>
              </name>
            </person-group>
            <article-title>Perioperative Management of Pheochromocytoma.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>1427</fpage>
            <page-range>1427-1439</page-range>
            <pub-id pub-id-type="pmid">28392094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lepor</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.</article-title>
            <source>Urol Clin North Am</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-23</page-range>
            <pub-id pub-id-type="pmid">27476124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frishman</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Kotob</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Alpha-adrenergic blocking drugs in clinical medicine.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-16</page-range>
            <pub-id pub-id-type="pmid">9987696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christou</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Tsinopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ziakas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tzamalis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative Floppy Iris Syndrome: Updated Perspectives.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2020</year>
            <volume>14</volume>
            <fpage>463</fpage>
            <page-range>463-471</page-range>
            <pub-id pub-id-type="pmid">32109982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMillian</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Trombley</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Charash</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Christian</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Phentolamine continuous infusion in a patient with pheochromocytoma.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2011</year>
            <month>Jan</month>
            <day>15</day>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-4</page-range>
            <pub-id pub-id-type="pmid">21200059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramirez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Severe hypotension associated with &#x003b1; blocker tamsulosin.</article-title>
            <source>BMJ</source>
            <year>2013</year>
            <month>Nov</month>
            <day>05</day>
            <volume>347</volume>
            <fpage>f6492</fpage>
            <pub-id pub-id-type="pmid">24192968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17401.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Orthostatic Hypotension: A Practical Approach to Investigation and Management.</article-title>
            <source>Can J Cardiol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>1725</fpage>
            <page-range>1725-1728</page-range>
            <pub-id pub-id-type="pmid">28807522</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
